4.8 Article

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

期刊

NATURE MEDICINE
卷 28, 期 6, 页码 1224-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01788-1

关键词

-

资金

  1. French National Research Agency (ANR)
  2. Agence Regionale de Sante (ARS) Ile-de-France
  3. Philanthropia Lombard Odier Foundation
  4. Novartis
  5. AstraZeneca

向作者/读者索取更多资源

The phase 3 CAPRI clinical trial demonstrates that remote monitoring using a digital nurse navigator-led system improves patient care experience and optimizes healthcare resources for individuals receiving oral anticancer treatment. The intervention leads to increased treatment dose adherence, reduced hospitalization days, and decreased treatment-related toxicities, highlighting the potential benefits of patient-centered care through remote monitoring.
The phase 3 CAPRI clinical trial evaluating the impact of a digital nurse navigator-led system in patients receiving oral anticancer treatment shows that remote monitoring using a smartphone app results in an improved patient care experience and optimizes healthcare resources. Strategies that individualize the care of cancer patients receiving oral anticancer agents offer opportunities to improve treatment adherence and patient care. However, the impact of digital remote monitoring systems in this setting has not been evaluated. Here, we report the results of a phase 3 trial (CAPRI, NCT02828462) to assess the impact of a nurse navigator-led program on treatment delivery for patients with metastatic cancer. Patients receiving approved oral anticancer agents were randomized (1:1) to an intervention combining a nurse navigator-led follow-up system and a web portal-smartphone application on top of usual care, or to usual symptom monitoring at the discretion of the treating oncologist, for a duration of 6 months. The primary objective included optimization of the treatment dose. Secondary objectives were grade >= 3 toxicities, patient experience, rates and duration of hospitalization, response and survival, and quality of life. In 559 evaluable patients the relative dose intensity was higher in the experimental arm (93.4% versus 89.4%, P = 0.04). The intervention improved the patient experience (Patient Assessment of Chronic Illness Care score, 2.94 versus 2.67, P = 0.01), reduced the days of hospitalization (2.82 versus 4.44 days, P = 0.02), and decreased treatment-related grade >= 3 toxicities (27.6% versus 36.9%, P = 0.02). These findings show that patient-centered care through remote monitoring of symptoms and treatment may improve patient outcomes and experience.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据